NCT02271113View on ClinicalTrials.gov

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

GMI-1271

DRUG

Placebo

DRUG

Enoxaparin Sodium (Lovenox®)

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

University of Michigan

OTHER

lead

GlycoMimetics Incorporated

INDUSTRY

NCT02271113 - Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter